Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD

33.01  +0.69 (+2.13%)

After market: 33.01 0 (0%)

Fundamental Rating

3

Taking everything into account, CRNX scores 3 out of 10 in our fundamental rating. CRNX was compared to 559 industry peers in the Biotechnology industry. CRNX has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRNX has reported negative net income.
CRNX had a negative operating cash flow in the past year.
In the past 5 years CRNX always reported negative net income.
CRNX had a negative operating cash flow in each of the past 5 years.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.11%, CRNX is in the better half of the industry, outperforming 74.78% of the companies in the same industry.
With an excellent Return On Equity value of -26.18%, CRNX belongs to the best of the industry, outperforming 81.04% of the companies in the same industry.
Industry RankSector Rank
ROA -24.11%
ROE -26.18%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

CRNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRNX has been increased compared to 1 year ago.
The number of shares outstanding for CRNX has been increased compared to 5 years ago.
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 16.38 indicates that CRNX is not in any danger for bankruptcy at the moment.
The Altman-Z score of CRNX (16.38) is better than 91.06% of its industry peers.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.38
ROIC/WACCN/A
WACC9.58%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

CRNX has a Current Ratio of 22.53. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
CRNX has a Current ratio of 22.53. This is amongst the best in the industry. CRNX outperforms 95.35% of its industry peers.
A Quick Ratio of 22.53 indicates that CRNX has no problem at all paying its short term obligations.
CRNX has a better Quick ratio (22.53) than 95.35% of its industry peers.
Industry RankSector Rank
Current Ratio 22.53
Quick Ratio 22.53
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.06%.
CRNX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.62%.
CRNX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.68% yearly.
EPS 1Y (TTM)-1.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
Revenue 1Y (TTM)-61.62%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%-43.59%

3.2 Future

Based on estimates for the next years, CRNX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.10% on average per year.
Based on estimates for the next years, CRNX will show a very strong growth in Revenue. The Revenue will grow by 271.95% on average per year.
EPS Next Y-22.02%
EPS Next 2Y-13.73%
EPS Next 3Y4.66%
EPS Next 5Y25.1%
Revenue Next Year210.54%
Revenue Next 2Y420.04%
Revenue Next 3Y398.76%
Revenue Next 5Y271.95%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.73%
EPS Next 3Y4.66%

More info and screens

0

5. Dividend

5.1 Amount

CRNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (6/6/2025, 8:00:01 PM)

After market: 33.01 0 (0%)

33.01

+0.69 (+2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners108.5%
Inst Owner Change2.48%
Ins Owners1.91%
Ins Owner Change19.66%
Market Cap3.09B
Analysts85.22
Price Target75.55 (128.87%)
Short Float %11.19%
Short Ratio9.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.7%
Min EPS beat(2)-8.34%
Max EPS beat(2)2.94%
EPS beat(4)1
Avg EPS beat(4)-4.01%
Min EPS beat(4)-8.34%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.72%
EPS beat(12)2
Avg EPS beat(12)-5.54%
EPS beat(16)3
Avg EPS beat(16)-6.6%
Revenue beat(2)1
Avg Revenue beat(2)94.65%
Min Revenue beat(2)-100%
Max Revenue beat(2)289.31%
Revenue beat(4)1
Avg Revenue beat(4)16.5%
Min Revenue beat(4)-100%
Max Revenue beat(4)289.31%
Revenue beat(8)4
Avg Revenue beat(8)44.77%
Revenue beat(12)7
Avg Revenue beat(12)111.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.35%
PT rev (3m)-2.63%
EPS NQ rev (1m)-6.83%
EPS NQ rev (3m)-11.26%
EPS NY rev (1m)-8.37%
EPS NY rev (3m)-14.77%
Revenue NQ rev (1m)47.58%
Revenue NQ rev (3m)544%
Revenue NY rev (1m)10.02%
Revenue NY rev (3m)1.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4068.92
P/FCF N/A
P/OCF N/A
P/B 2.47
P/tB 2.47
EV/EBITDA N/A
EPS(TTM)-3.82
EYN/A
EPS(NY)-4.8
Fwd EYN/A
FCF(TTM)-2.83
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.01
BVpS13.39
TBVpS13.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.11%
ROE -26.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 115.92%
Cap/Sales 493.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.53
Quick Ratio 22.53
Altman-Z 16.38
F-Score3
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.83%
EPS Next Y-22.02%
EPS Next 2Y-13.73%
EPS Next 3Y4.66%
EPS Next 5Y25.1%
Revenue 1Y (TTM)-61.62%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%-43.59%
Revenue Next Year210.54%
Revenue Next 2Y420.04%
Revenue Next 3Y398.76%
Revenue Next 5Y271.95%
EBIT growth 1Y-51.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.02%
EBIT Next 3Y0.03%
EBIT Next 5YN/A
FCF growth 1Y-84.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.7%
OCF growth 3YN/A
OCF growth 5YN/A